Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.

Martine HoogendoornIsaac Corro RamosStéphane SoulardJennifer CookErkki SoiniEmma PaulssonMaureen P M H Rutten-van Mölken

Published in: BMJ open (2021)

Based on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

Keyphrases

chronic obstructive pulmonary disease
combination therapy
randomized controlled trial
molecular dynamics
lung function